The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...

Please provide your email address to receive an email when new articles are posted on . Infusion-related reactions occurred at similar rates for 30-minute and 10-minute pembrolizumab infusions.

William Smith is a flesh and blood writer who hasn't seen natural sunlight in months. He spends every waking hour at his laptop producing content to satisfy the cruel algorithm and to give those who ...

Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications. In this episode, experts begin outlining how bispecific ...

2025 was a banner year for action games. From a surprise breakout Soulslike with one of the hardest-hitting and most brutal combat systems the genre has ever seen, to the hotly anticipated follow-up ...

Following on from the wonderful It Takes Two, developer Hazelight took things to the next level when it comes to scale in Split Fiction and continued to hone its craft as the modern-day masters of the ...

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that it ...